Biopharmaceutical and healthcare technology company Roivant Sciences filed an S-4 registration on its proposed business combination with Montes Archimedes Acquistion.
The new enterprise would have a valuation of approximately $5 billion.
Announced earlier this month, the transaction includes $411 million in the SPAC’s trust and a concurrent, fully-committed $200 million PIPE from healthcare investors including Fidelity Management & Research Company, Eventide Asset Management, Suvretta Capital, RTW Investments, Viking Global Investors, and SB Management, a subsidiary of SoftBank Group, as well as strategic investors including Sumitomo Dainippon Pharma and Palantir Technologies.
The SPAC’s sponsor, Patient Square Capital, and key Roivant equity holders and management have agreed to long-term lockups, with at least 50 percent of their holdings locked up for three years. Read more.
